Tech Company Financing Transactions
Cardiac Dimensions Funding Round
Cardiac Dimensions, operating out of Kirkland, secured $15.2 million from Aperture Venture Partners, Life Sciences Partners and private investors.
Transaction Overview
Company Name
Announced On
3/11/2015
Transaction Type
Venture Equity
Amount
$15,200,000
Round
Undisclosed
Proceeds Purpose
The proceeds will be used to support the company's REDUCE FMR clinical trial. REDUCE FMR is the first blinded, randomized clinical trial of a percutaneous mitral repair device in patients with functional mitral regurgitation (FMR). Involving up to 20 leading hospitals in Europe and Australia, REDUCE FMR is being initiated with the objective to establish CARILLON as the gold standard therapy in the treatment of FMR. The proceeds will also be used to expand the company's research and development projects and its commercial operations.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
5540 Lake Washington Blvd. Northeast
Kirkland, WA 98033
USA
Kirkland, WA 98033
USA
Phone
Website
Email Address
Overview
The CARILLON Mitral Contour System is a groundbreaking, non-surgical device developed to treat functional mitral regurgitation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Wypych
Chief Medical Officer
Steven Goldberg
Vice President
Gretchen Gary
VP - Operations
Bob Calcote
VP - Regulatory Affairs
Matthew Stark
VP - Sales
Carmelo Mastrandrea
Browse more venture capital transactions:
Prev: 3/11/2015: innRoad venture capital transaction
Next: 3/12/2015: Actelis Networks venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs